Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2005.00570.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
Blood Adv
October 2023
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA.
Article Synopsis
- * Researchers developed off-the-shelf, frozen NK cells armed with a chimeric antigen receptor (CAR) that also secretes interleukin-15 (IL-15), enhancing their effectiveness against AML cells.
- * The engineered NK cells showed improved survival rates in AML models and were not harmful to healthy cells, indicating they could represent a promising new strategy for AML treatment.
The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy.
Front Cell Dev Biol
March 2021
Spanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain.
Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Although the therapeutic efficacy of these cells has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. On the other hand, diverse controversial issues on the biology and clinical applications of MSCs, including their specific phenotype, the requirement of an inflammatory environment to induce immunosuppression, the relevance of the cell dose and their administration schedule, the cell delivery route (intravascular/systemic vs.
View Article and Find Full Text PDFThe Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality Attributes.
Front Immunol
October 2020
Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland.
Article Synopsis
- Recent reports indicate that cryopreserved mesenchymal stromal cells (MSCs) may function less effectively than fresh MSCs, though cryopreservation allows for quicker access and better quality control before use.
- In our study of in-house manufactured MSCs, we found that our protocols maintain high cell viability and recovery post-thaw, although there is a notable reduction in immunosuppressive performance.
- Repeated freezing (up to two times) does not significantly compromise MSC quality, but excessive freezing (four or more times) could lead to premature aging of the cells.
Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease.
PLoS One
June 2016
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
The adoptive transfer of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in murine models of allogeneic hematopoietic cell transplantation (HCT) has been shown to protect recipient mice from lethal acute graft-versus-host disease (GVHD) and this approach is being actively investigated in human clinical trials. Here, we examined the effects of cryopreservation on Tregs. We found that freeze and thaw of murine and human Tregs is associated with reduced expression of L-selectin (CD62L), which was previously established to be an important factor that contributes to the in vivo protective effects of Tregs.
View Article and Find Full Text PDFLate driveline left ventricular assist device infection treated with frozen-and-thawed allogeneic platelet gel.
Interact Cardiovasc Thorac Surg
September 2014
Cardiac Surgery Unit, Department of Surgery and Translational Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
In this case report, we report the application of frozen-and-thawed allogeneic platelet gel (PLT-gel) to treat a late driveline exit site infection in a 56-year old patient supported by a Heartware-HVAD left ventricular assist device. The treatment duration was 4 weeks and at the follow-up the skin around the exit site was free from further infection. PLT-gel can be used to treat local infection of the driveline exit site and to prevent further high-risk infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!